MTVA
MetaVia Inc.
Set alert
- YTD
- -86.70%
- 1 year
- -89.56%
- Open
- 1.23
- Prev close
- 1.19
- Mkt cap
- 7.38M
- Vol
- 74.06K
- Avg vol
- 78.06K
- EPS
- -3.65
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.12
- High
- 1.29
- Forward P/E
- 0.00
- Beta
- -0.28
- Short ratio
- 0.65
- Inst. own
- 12.71%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.50
- 200-d avg
- 3.54
- 1y target
- 17.33
Key statistics
- Market cap
- 14.04M
- Enterprise value
- -7.74M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.08
- EPS (TTM)
- -4.29
- Beta
- -0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 21.67M
- Total debt
- 154.00K
- Return on equity
- -160.76%
- Shares outstanding
- 8.62M
- Short % of float
- 0.67%
- 50-day average
- 2.50
- 200-day average
- 3.54
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 17.33
- Target (high)
- 23.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About MetaVia Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metaviatx.com
News
- MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026
- MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026
- 12 Health Care Stocks Moving In Monday's After-Market Session
- MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer
- MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
- MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
- MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- BioStem Technologies Announces Appointment of Three New Members to its Board of Directors
Your note
Sign in to keep a note on MTVA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 5,347,790 |
| GLICKMAN MARK A | Director | Stock Award(Grant) | Jun 6, 2024 | 9,740 |
| GROVES JASON L | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
| KIM HYUNG HEON | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 625,064 |
| KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 26, 2023 | 302,013 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.84% | 848,000 | 1.38M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 1.04% | 89,222 | 145.43K | Sep 29, 2024 |
| Vanguard Group Inc | 0.70% | 60,452 | 98.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.38% | 32,574 | 53.09K | Sep 29, 2024 |
| Ferguson Wellman Capital Management, Inc. | 0.18% | 15,670 | 25.54K | Sep 29, 2024 |
| State Street Corporation | 0.18% | 15,633 | 25.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.38% | 32,432 | 52.86K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.33% | 28,020 | 45.67K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 19,569 | 31.90K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 4,747 | 7.74K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 4,751 | 7.74K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 4,667 | 7.61K | Oct 30, 2024 |